Navigation Links
Signalife Announces Anticipated Date of Transition to OTCBB
Date:9/8/2008

LOS ANGELES, Sept. 8 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) announced that it has filed its Form 25 with the Securities and Exchange Commission effecting the withdrawal of trading of its common stock on the American Stock Exchange ("AMEX"). The last day that Signalife's common stock will trade on AMEX will be Friday, September 12, 2008. Signalife expects that the company's common stock will be available for quotation on both the Over-The-Counter Bulletin Board and the Pink Sheets commencing upon the opening of market on Monday, September 15, 2008. Pursuant to OTCBB policy, it will assign a new trading symbol for Signalife's common stock following the close of trading on AMEX on Friday, September 12, 2008. Signalife will publicly announce the new trading symbol promptly upon receipt from the OTCBB.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease. More information is located at http://www.signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause the companies' actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, the failure of Signalife's market maker to complete or timely complete the process of qualifying the shares for quotation on the OTCBB, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating the companies' technology and procure market acceptance for these products, failure to obtain federal or state or governmental or international regulatory approvals governing heart monitoring and other biomedical devices incorporating the technology, failure to obtain import and export capabilities in the various countries containing buyers and resellers and hospitals and clinics and doctors for the devices, inability to obtain physician, patient or insurance acceptance of or for heart monitoring and other biomedical incorporating of the technologies, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical and information solutions incorporating the companies' technologies. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Provides Corporate Update
2. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
3. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
4. Signalife Achieves $1.98 Million Sales Orders Thus Far
5. Signalife Receives Another $3.3 Million Sales Orders
6. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
7. Signalife Continues to Procure Purchase Orders, Revenues
8. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
9. U.S. Patent 7,299,083 Awarded to Signalife
10. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
11. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... , ... Scientists at two major cancer research centers say older patients who ... who are younger. Surviving Mesothelioma has just published an article on the new research. ... Stanford Universities analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database to ...
(Date:5/31/2016)... ... , ... The Academy of Model Aeronautics is thrilled to announce a new ... through Labor Day 2016. Bill Chaffee’s Boeing P-12B will be exhibited thanks to a ... first place for Senior Scale Model at the 1930 National Airplane Model League of ...
(Date:5/27/2016)... ... 2016 , ... PBI-Gordon Corporation is pleased to announce Dave Loecke has accepted ... career with PBI-Gordon, Dave has served in a wide variety of roles. His most ... and launch of many of PBI-Gordon’s most successful products. , “Dave has been essential ...
(Date:5/27/2016)... 2016 At present, the Biotech sphere ... space know that volatility is what makes this industry interesting ... Synta Pharmaceuticals Corp. (NASDAQ: SNTA ), CTI BioPharma ... LPTN ), and Heat Biologics Inc. (NASDAQ: ... technical alerts for these stocks at: http://www.activewallst.com/register/ ...
Breaking Biology Technology:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
Breaking Biology News(10 mins):